Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced the clinical launch of the ArteraAI Prostate Test (mHSPC). The CLIA-certified and CAP-accredited prognostic test will...

Grundium Acquires Visiopharm: The combined platform brings together digital slide scanning and AI-driven precision pathology software to accelerate accessible and scalable adoption of precision diagnostics TAMPERE, FI AND COPENHAGEN, DK...

Taylor & Francis is pleased to invite you to submit your work to an upcoming Article Collection on “Breast cancer biomarkers in diagnostic and translational pathology” in the journal Breast Cancer: Targets and Therapy. This Article...

SINGAPORE, May 18, 2026 /PRNewswire/ -- AstraZeneca and Roche Diagnostics Asia Pacific today announced a three-year Memorandum of Understanding to help advance digital pathology capabilities and elevate cancer care across nine Asia markets,...

From LinkedIn regarding Techcyte and Biobase partnership Sam Seymour, CPO and Co-Founder at Biobase: I started in digital pathology over 6 years ago at Paige (now Tempus AI). Not a lot has changed since then; digital pathology's adoption...

OREM, UT, UNITED STATES, May 4, 2026 /EINPresswire.com/ -- Techcyte is pleased to announce that a validation study conducted by the Contra Costa County Public Health Laboratory (CCPHL) evaluating its AI-assisted ova and parasite (O&P)...